公开(公告)号：US11925174B2

公开(公告)日：2024-03-12

申请号：US15868885

申请日：2018-01-11

Applicant: Merus N.V.

Inventor： Ton Logtenberg ,  Rui Daniel Pinto ,  Erwin Houtzager

IPC: A01K67/027 ,  C07K16/00 ,  C07K16/46 ,  C12N5/10 ,  C12N15/85 ,  C07K14/47 ,  C07K16/10 ,  C07K16/12 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C12P21/00 ,  G01N33/569

CPC classification number: A01K67/0278 ,  A01K67/027 ,  A01K67/0275 ,  C07K16/00 ,  C07K16/462 ,  C12N5/10 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/01 ,  C07K14/47 ,  C07K16/005 ,  C07K16/10 ,  C07K16/1282 ,  C07K16/22 ,  C07K16/248 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/10 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/94 ,  C07K2319/00 ,  C12P21/00 ,  G01N33/56966

Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.

公开(公告)号：US11834713B2

公开(公告)日：2023-12-05

申请号：US17383975

申请日：2021-07-23

Applicant: EUROPEAN MOLECULAR BIOLOGY LABORATORY

Inventor： Paul Heppenstall ,  Shane Morley

IPC: C12Q1/6886 ,  C12Q1/6876 ,  A01K67/027 ,  G01N33/573

CPC classification number: C12Q1/6876 ,  A01K67/0276 ,  G01N33/573 ,  A01K2217/075 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0356 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2333/91051

Abstract: The present invention pertains to novel analgesics useful for treating mechanical pain. The invention suggests the use of inhibitors of α-tubulin acetylation for inhibition of neurological sensations that are mediated by sensory neurons. The perception of mechanical pain is can be modulated by altering the α-tubulin acetylation, in context of the invention in particular by modulation of the expression and/or activity of the enzyme α-tubulin acetyltransferase (Atat). The invention provides the medical application of α-tubulin acetyltransferase inhibitors as analgesics and a screening method for the identification of compounds useful in the treatment of pain.

公开(公告)号：US11834647B2

公开(公告)日：2023-12-05

申请号：US17021158

申请日：2020-09-15

Applicant: National Pingtung University of Science and Technology

Inventor： Hso-Chi Chaung ,  Wen-Bin Chung ,  Ann Ying-An Chen ,  Mei-Li Wu

IPC: C12N5/0783 ,  G01N33/50 ,  C12N5/0786 ,  G01N33/68 ,  A01K67/027

CPC classification number: C12N5/0638 ,  A01K67/0278 ,  C12N5/0637 ,  C12N5/0645 ,  C12N5/0646 ,  G01N33/5047 ,  G01N33/6869 ,  A01K2207/15 ,  A01K2217/206 ,  A01K2227/108 ,  A01K2267/0387

Abstract: The present invention relates to an in vitro immune synapse system and a method of in vitro evaluating immune response using the same. The in vitro immune synapse system includes antigen-presenting cells (APCs) and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), all of which is from a same individual of pigs. When a test sample is co-cultured in the in vitro immune synapse system for a given period, it can be determined that the test sample is immunogenic, immunostimulatory or not according to the immunization-related changes of these cells, thereby potentially replacing some kinds of animal experimentation.

公开(公告)号：US11800858B2

公开(公告)日：2023-10-31

申请号：US16643184

申请日：2018-07-20

Applicant: Korea University Research and Business Foundation

Inventor： Jae-Yong Park ,  Eun Mi Hwang ,  Heh-In Im ,  Chang-Hoon Cho ,  Sangjoon Lee

IPC: A01K67/027 ,  A61K49/00 ,  C07K14/47 ,  C07K14/705 ,  G01N33/68 ,  G01N33/50

CPC classification number: A01K67/0276 ,  A61K49/0008 ,  C07K14/47 ,  C07K14/705 ,  G01N33/5088 ,  G01N33/6896 ,  A01K2217/054 ,  A01K2217/075 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0318 ,  A01K2267/0356 ,  G01N2800/302

Abstract: The present invention relates to: A schizophrenia animal model wherein the model is a mouse in which an anoctamin 1 (ANO1) gene is knocked out in cholinergic neurons of a medial habenula; and a preparation method therefor and the like. The schizophrenia animal model according to the present invention targets the medial habenula which is brain tissue playing a major role in the pathogenesis of schizophrenia, and it has been confirmed that when the ANO1 gene is specifically knocked out in the cholinergic neurons of the medial habenula, positive, negative and cognitive symptoms of schizophrenia are observed, thereby confirming that schizophrenia has been induced. Therefore, the animal model of the present invention is expected to be effectively useful in schizophrenia pathogenesis research and therapeutic agent development and screening.

公开(公告)号：US11655288B2

公开(公告)日：2023-05-23

申请号：US15991792

申请日：2018-05-29

Applicant: The Regents of the University of California

Inventor： Joseph L. Witztum ,  Sotirios Tsimikas ,  Xuchu Que

IPC: C07K16/18 ,  A01K67/027 ,  A61K39/00

CPC classification number: C07K16/18 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0362 ,  A01K2267/0368 ,  A01K2267/0375 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76

Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.

公开(公告)号：US20230141187A1

公开(公告)日：2023-05-11

申请号：US17917992

申请日：2021-04-21

Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education

Inventor： Jie Liu ,  Toren Finkel

IPC: A01K67/027 ,  C12N9/00

CPC classification number: A01K67/0275 ,  C12Y603/04015 ,  C12N9/93 ,  A01K2217/206 ,  A01K2267/0393 ,  C07K2319/02 ,  C07K2319/04 ,  C07K2319/40 ,  A01K2227/103 ,  A01K2217/15

Abstract: This document relates to methods and materials involved in the deconvolution of serum. For example, transgenic non-human animals (e g , transgenic mice) that secrete tagged (e.g., biotinylated) molecules from a particular tissue are provided.

公开(公告)号：US20190014756A1

公开(公告)日：2019-01-17

申请号：US15650073

申请日：2017-07-14

Applicant: Tai-Jay Chang

Inventor： Tai-Jay Chang

IPC: A01K67/027 ,  C07K14/705 ,  C12N15/63

CPC classification number: A01K67/027 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0331 ,  C07K14/00 ,  C07K14/705 ,  C07K14/721 ,  C12N15/00 ,  C12N15/63 ,  C12N2800/107 ,  C12N2830/008

Abstract: A non-human transgenic animal that contains in its genome a nucleic acid encoding human ARCAP operably linked to a liver-specific promoter. The transgenic animal expresses the human ARCAP protein and develops tumors of the liver, spleen, abdomen, or lymph. Also provided is a cell line derived from the non-human transgenic animal expressing the human ARCAP gene. Further provided is a method for producing a transgenic mouse by micro-injecting into a fertilized mouse oocyte a vector that contains a human ARCAP cDNA operably linked to a liver-specific promoter and transferring the micro-injected mouse oocyte into a foster mouse.

公开(公告)号：US20180334498A1

公开(公告)日：2018-11-22

申请号：US15991721

申请日：2018-05-29

Applicant: The Regents of the University of California

Inventor： Joseph L. Witztum ,  Sotirios Tsimikas ,  Xuchu Que

IPC: C07K16/18 ,  A01K67/027 ,  A61K39/00

CPC classification number: C07K16/18 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0362 ,  A01K2267/0368 ,  A01K2267/0375 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76

Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.

公开(公告)号：US10034921B2

公开(公告)日：2018-07-31

申请号：US14767100

申请日：2014-02-13

Applicant: Laboratoire Français du Fractionnement et des Biotechnologies

Inventor： Li-How Chen ,  Harry M. Meade

IPC: G01N33/00 ,  A01K67/033 ,  A61K38/45 ,  A01K67/027 ,  C12N9/10 ,  C07K14/81

CPC classification number: A61K38/45 ,  A01K67/0275 ,  A01K2207/05 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2267/01 ,  C07K14/8125 ,  C12N9/1081 ,  C12Y204/99

Abstract: In one aspect, the disclosure provides proteins with modified glycosylation and methods of their production. In aspect, the disclosure provides transgenic animals and cells for the production of proteins with modified glycosylation. In some embodiment, the modified glycosylation is increased sialylation.

公开(公告)号：US10004212B2

公开(公告)日：2018-06-26

申请号：US15494738

申请日：2017-04-24

Applicant: University of Iowa Research Foundation

Inventor： Michael J. Welsh ,  David Stoltz

IPC: A01K67/027

CPC classification number: A01K67/0278 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/056 ,  A01K2217/072 ,  A01K2217/077 ,  A01K2217/206 ,  A01K2227/108 ,  A01K2267/0306 ,  C12N15/85 ,  G01N33/502

Abstract: This invention relates to transgenic pig models of cystic fibrosis, cells that can be used to make such animals, and methods of making and using these pigs and cells.